Suppr超能文献

活性氧调节核干细胞寡聚化和蛋白质降解。

Reactive oxygen species regulate nucleostemin oligomerization and protein degradation.

机构信息

Department of Medicine, Divisions of Oncology and Hematology, Stanford University School of Medicine, Stanford, California 94305, USA.

出版信息

J Biol Chem. 2011 Apr 1;286(13):11035-46. doi: 10.1074/jbc.M110.208470. Epub 2011 Jan 17.

Abstract

Nucleostemin (NS) is a nucleolar-nucleoplasmic shuttle protein that regulates cell proliferation, binds p53 and Mdm2, and is highly expressed in tumor cells. We have identified NS as a target of oxidative regulation in transformed hematopoietic cells. NS oligomerization occurs in HL-60 leukemic cells and Raji B lymphoblasts that express high levels of c-Myc and have high intrinsic levels of reactive oxygen species (ROS); reducing agents dissociate NS into monomers and dimers. Exposure of U2OS osteosarcoma cells with low levels of intrinsic ROS to hydrogen peroxide (H(2)O(2)) induces thiol-reversible disulfide bond-mediated oligomerization of NS. Increased exposure to H(2)O(2) impairs NS degradation, immobilizes the protein within the nucleolus, and results in detergent-insoluble NS. The regulation of NS by ROS was validated in a murine lymphoma tumor model in which c-Myc is overexpressed and in CD34+ cells from patients with chronic myelogenous leukemia in blast crisis. In both instances, increased ROS levels were associated with markedly increased expression of NS protein and thiol-reversible oligomerization. Site-directed mutagenesis of critical cysteine-containing regions of nucleostemin altered both its intracellular localization and its stability. MG132, a potent proteasome inhibitor and activator of ROS, markedly decreased degradation and increased nucleolar retention of NS mutants, whereas N-acetyl-L-cysteine largely prevented the effects of MG132. These results indicate that NS is a highly redox-sensitive protein. Increased intracellular ROS levels, such as those that result from oncogenic transformation in hematopoietic malignancies, regulate the ability of NS to oligomerize, prevent its degradation, and may alter its ability to regulate cell proliferation.

摘要

核干细胞蛋白 (NS) 是一种核仁-核质穿梭蛋白,可调节细胞增殖,与 p53 和 Mdm2 结合,在肿瘤细胞中高度表达。我们已经确定 NS 是转化造血细胞中氧化调节的靶标。HL-60 白血病细胞和 Raji B 淋巴母细胞中 NS 发生寡聚化,这些细胞表达高水平的 c-Myc,并且具有高内在活性氧 (ROS) 水平;还原剂将 NS 解离为单体和二聚体。用低水平内在 ROS 的 U2OS 骨肉瘤细胞暴露于过氧化氢 (H₂O₂) 可诱导 NS 的巯基可逆二硫键介导的寡聚化。增加对 H₂O₂的暴露会损害 NS 的降解,使蛋白质固定在核仁内,并导致去污剂不溶性 NS。ROS 对 NS 的调节在过表达 c-Myc 的小鼠淋巴瘤肿瘤模型和慢性髓性白血病急变期的 CD34+细胞中得到了验证。在这两种情况下,ROS 水平的增加与 NS 蛋白表达和巯基可逆寡聚化的显著增加相关。核干细胞蛋白关键半胱氨酸残基的定点突变改变了其细胞内定位及其稳定性。MG132 是一种有效的蛋白酶体抑制剂和 ROS 激活剂,可显著减少 NS 突变体的降解并增加核仁保留,而 N-乙酰-L-半胱氨酸则在很大程度上阻止了 MG132 的作用。这些结果表明 NS 是一种高度的氧化还原敏感蛋白。造血恶性肿瘤中致癌转化导致的细胞内 ROS 水平增加可调节 NS 寡聚化的能力,防止其降解,并可能改变其调节细胞增殖的能力。

相似文献

1
Reactive oxygen species regulate nucleostemin oligomerization and protein degradation.
J Biol Chem. 2011 Apr 1;286(13):11035-46. doi: 10.1074/jbc.M110.208470. Epub 2011 Jan 17.
2
Ubiquitin- and MDM2 E3 ligase-independent proteasomal turnover of nucleostemin in response to GTP depletion.
J Biol Chem. 2012 Mar 23;287(13):10013-10020. doi: 10.1074/jbc.M111.335141. Epub 2012 Feb 8.
3
Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.
Cancer Res. 2009 Apr 1;69(7):3004-12. doi: 10.1158/0008-5472.CAN-08-3413. Epub 2009 Mar 24.
4
Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.
Oncogene. 2012 Jul 12;31(28):3311-21. doi: 10.1038/onc.2011.507. Epub 2011 Nov 14.
5
ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors.
Biochem J. 2013 Sep 1;454(2):201-8. doi: 10.1042/BJ20130282.
8
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Blood. 2001 Apr 1;97(7):2084-90. doi: 10.1182/blood.v97.7.2084.
10
Transcriptional control of a stem cell factor nucleostemin in liver regeneration and aging.
PLoS One. 2024 Sep 11;19(9):e0310219. doi: 10.1371/journal.pone.0310219. eCollection 2024.

引用本文的文献

2
Zinc-α2-glycoprotein as an inhibitor of amine oxidase copper-containing 3.
Open Biol. 2020 Apr;10(4):190035. doi: 10.1098/rsob.190035. Epub 2020 Apr 22.
3
Differential expression of nucleostemin in the cytoplasm and nuclei of normal and cancerous cell lines.
Turk J Biol. 2018 Jun 13;42(3):250-258. doi: 10.3906/biy-1712-10. eCollection 2018.
4
Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.
Oncotarget. 2016 Nov 15;7(46):74917-74930. doi: 10.18632/oncotarget.12493.
5
FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Breast Cancer Res. 2015 Mar 28;17:47. doi: 10.1186/s13058-015-0551-x.

本文引用的文献

1
Molecular basis of coiled-coil oligomerization-state specificity.
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19850-5. doi: 10.1073/pnas.1008502107. Epub 2010 Nov 2.
2
Studies on biomarkers for oxidative stress in patients with chronic myeloid leukemia.
Hematol Oncol Stem Cell Ther. 2009;2(1):285-8. doi: 10.1016/s1658-3876(09)50039-8.
4
Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710.
Cell Prolif. 2009 Dec;42(6):762-9. doi: 10.1111/j.1365-2184.2009.00635.x. Epub 2009 Aug 25.
6
Nucleostemin: a latecomer with new tricks.
Int J Biochem Cell Biol. 2009 Nov;41(11):2122-4. doi: 10.1016/j.biocel.2009.05.020. Epub 2009 Jun 6.
7
Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.
Cancer Res. 2009 Apr 1;69(7):3004-12. doi: 10.1158/0008-5472.CAN-08-3413. Epub 2009 Mar 24.
8
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
Leukemia. 2009 Aug;23(8):1432-40. doi: 10.1038/leu.2009.49. Epub 2009 Mar 19.
9
Critical role of nucleostemin in pre-rRNA processing.
J Biol Chem. 2009 Feb 20;284(8):4968-77. doi: 10.1074/jbc.M804594200. Epub 2008 Dec 23.
10
Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc.
J Biol Chem. 2009 Mar 6;284(10):6520-9. doi: 10.1074/jbc.M807564200. Epub 2008 Dec 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验